Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials

[1] McCarberg BH(2001)Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia Am J Ther 8 181-186

[2] Barkin RL(2009)Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain Pain Pract 9 71-81

[3] Nicholson B(2006)Extended-release opioids for the management of chronic non-malignant pain Expert Opin Drug Deliv 3 489-497

[4] Sloan P(2010)Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain Clin Drug Investig 30 31-38

[5] Babul N(2001)Pharmacology of oral combination analgesics: rational therapy for pain J Clin Pharm Ther 26 257-264

[6] Gatti A(2014)Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer, biphasic, IR/ER combination formulation, under fed and fasted conditions Drug Des Devel Ther 8 1125-1134

[7] Dauri M(2015)Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers Clin Pharmacol 7 1-9

[8] Leonardis F(2003)Side effects of opioids during short-term administration: effect of age, gender, and race Clin Pharmacol Ther 74 102-112

[9] Longo G(2012)Sex and gender aspects in anesthetics and pain medication Handb Exp Pharmacol 214 265-278

[10] Marinangeli F(2005)Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial Acad Emerg Med 12 282-288

[1] McCarberg BH(2001)Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia Am J Ther 8 181-186

[2] Barkin RL(2009)Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain Pain Pract 9 71-81

[3] Nicholson B(2006)Extended-release opioids for the management of chronic non-malignant pain Expert Opin Drug Deliv 3 489-497

[4] Sloan P(2010)Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain Clin Drug Investig 30 31-38

[5] Babul N(2001)Pharmacology of oral combination analgesics: rational therapy for pain J Clin Pharm Ther 26 257-264

[6] Gatti A(2014)Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer, biphasic, IR/ER combination formulation, under fed and fasted conditions Drug Des Devel Ther 8 1125-1134

[7] Dauri M(2015)Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers Clin Pharmacol 7 1-9

[8] Leonardis F(2003)Side effects of opioids during short-term administration: effect of age, gender, and race Clin Pharmacol Ther 74 102-112

[9] Longo G(2012)Sex and gender aspects in anesthetics and pain medication Handb Exp Pharmacol 214 265-278

[10] Marinangeli F(2005)Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial Acad Emerg Med 12 282-288